IL6 and arteritis: Tocilizumab, a humanized anti-IL-6 R monoclonal antibody, for example, was the first drug to successfully block the IL-6 signal and was licenced by the US Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, systemic juvenile idiopathic and giant cell arteritis [35,36].